• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

用于侵袭性前列腺癌的前列腺特异性膜抗原（PSMA）成像生物标志物的当前状况

The Current Landscape of Prostate-Specific Membrane Antigen (PSMA) Imaging Biomarkers for Aggressive Prostate Cancer.

作者信息

Al Saffar Haidar, Chen David C, Delgado Carlos, Ingvar Jacob, Hofman Michael S, Lawrentschuk Nathan, Perera Marlon, Murphy Declan G, Eapen Renu

机构信息

Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, Australia.

Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, Australia.

出版信息

Cancers (Basel). 2024 Feb 26;16(5):939. doi: 10.3390/cancers16050939.

DOI:10.3390/cancers16050939
PMID:38473301
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10931387/
Abstract

The review examines the vital role of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in the diagnosis, staging, and treatment of prostate cancer (PCa). It focuses on the superior diagnostic abilities of PSMA PET/CT for identifying both nodal and distant PCa, and its potential as a prognostic indicator for biochemical recurrence and overall survival. Additionally, we focused on the variability of PSMA's expression and its impact on personalised treatment, particularly the use of [Lu] Lu-PSMA-617 radioligand therapy. This review emphasises the essential role of PSMA PET/CT in enhancing treatment approaches, improving patient outcomes, and reducing unnecessary interventions, positioning it as a key element in personalised PCa management.

摘要

本综述探讨了前列腺特异性膜抗原（PSMA）正电子发射断层扫描/计算机断层扫描（PET/CT）在前列腺癌（PCa）诊断、分期和治疗中的重要作用。它着重于PSMA PET/CT在识别淋巴结和远处PCa方面的卓越诊断能力，以及其作为生化复发和总生存预后指标的潜力。此外，我们关注了PSMA表达的变异性及其对个体化治疗的影响，特别是[Lu] Lu-PSMA-617放射性配体疗法的应用。本综述强调了PSMA PET/CT在优化治疗方案、改善患者预后及减少不必要干预方面的重要作用，使其成为个体化PCa管理的关键要素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ee3/10931387/74e3dda671d6/cancers-16-00939-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ee3/10931387/328fc46716bf/cancers-16-00939-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ee3/10931387/4bce9c4c4c7e/cancers-16-00939-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ee3/10931387/74e3dda671d6/cancers-16-00939-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ee3/10931387/328fc46716bf/cancers-16-00939-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ee3/10931387/4bce9c4c4c7e/cancers-16-00939-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ee3/10931387/74e3dda671d6/cancers-16-00939-g003.jpg

相似文献

1
The Current Landscape of Prostate-Specific Membrane Antigen (PSMA) Imaging Biomarkers for Aggressive Prostate Cancer.用于侵袭性前列腺癌的前列腺特异性膜抗原（PSMA）成像生物标志物的当前状况
Cancers (Basel). 2024 Feb 26;16(5):939. doi: 10.3390/cancers16050939.
2
EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [Lu]Lu-PSMA Radioligand Therapy.EAU-EANM 共识声明：前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描在前列腺癌患者及[Lu]Lu-PSMA 放射性配体治疗方面的作用
Eur Urol Oncol. 2022 Oct;5(5):530-536. doi: 10.1016/j.euo.2022.05.003. Epub 2022 Jun 11.
3
A Prospective Comparison of F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE).F-前列腺特异性膜抗原-1007 正电子发射断层扫描计算机断层扫描、全身 1.5T 磁共振成像弥散加权成像与传统成像单光子发射计算机断层扫描/计算机断层扫描在前列腺癌原发远处转移分期（PROSTAGE）中的前瞻性比较
Eur Urol Oncol. 2021 Aug;4(4):635-644. doi: 10.1016/j.euo.2020.06.012. Epub 2020 Jul 13.
4
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
5
Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描与常规成像在初治中高危前列腺癌分期中的比较：一项回顾性单中心研究。
Eur Urol Oncol. 2022 Oct;5(5):544-552. doi: 10.1016/j.euo.2020.08.012. Epub 2020 Sep 18.
6
Comparison of Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography for Primary Staging of Prostate Cancer: A Systematic Review and Meta-analysis.镓标记的前列腺特异性膜抗原配体正电子发射断层扫描/磁共振成像与正电子发射断层扫描/计算机断层扫描用于前列腺癌原发分期的比较：一项系统评价和荟萃分析
Eur Urol Open Sci. 2021 Sep 28;33:61-71. doi: 10.1016/j.euros.2021.09.006. eCollection 2021 Nov.
7
Fluorine-18-labelled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography or Magnetic Resonance Imaging to Diagnose and Localise Prostate Cancer. A Prospective Single-arm Paired Comparison (PEDAL).氟-18 标记的前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描或磁共振成像用于诊断和定位前列腺癌。一项前瞻性单臂配对比较（PEDAL）。
Eur Urol Oncol. 2024 Oct;7(5):1015-1023. doi: 10.1016/j.euo.2024.01.002. Epub 2024 Jan 27.
8
A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.一项前瞻性随机多中心研究，评估镓-68 前列腺特异性膜抗原（PSMA）PET/CT 成像在根治性手术或放疗前对高危前列腺癌分期的影响（proPSMA 研究）：临床试验方案。
BJU Int. 2018 Nov;122(5):783-793. doi: 10.1111/bju.14374. Epub 2018 Jun 3.
9
Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer.将前列腺特异性膜抗原正电子发射断层扫描纳入新诊断或生化复发前列腺癌男性管理决策中。
Eur Urol. 2023 Jun;83(6):521-533. doi: 10.1016/j.eururo.2022.10.024. Epub 2022 Nov 18.
10
Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis.前列腺特异性膜抗原正电子发射断层扫描与常规影像学方法在中高危前列腺癌初始分期中的诊断准确性的头对头比较：系统评价和荟萃分析。
Eur Urol. 2023 Jul;84(1):36-48. doi: 10.1016/j.eururo.2023.03.001. Epub 2023 Apr 7.

引用本文的文献

1
Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer.用于优化转移性去势抵抗性前列腺癌的PSMA靶向放射性配体疗法的生物标志物。
Front Oncol. 2025 Aug 20;15:1583168. doi: 10.3389/fonc.2025.1583168. eCollection 2025.
2
Prostate cancer immunotherapy-based strategies: an updated review emphasizing immune checkpoint inhibitors.基于免疫疗法的前列腺癌治疗策略：强调免疫检查点抑制剂的最新综述
Front Immunol. 2025 Jun 18;16:1583363. doi: 10.3389/fimmu.2025.1583363. eCollection 2025.
3
Long-term outcomes of PSMA PET/CT-guided radiotherapy in biochemical failure patients post-radical prostatectomy: a 5-year follow-up analysis.

本文引用的文献

1
Comparison of Nuclear Medicine Therapeutics Targeting PSMA among Alpha-Emitting Nuclides.比较 PSMA 靶向 α 发射核素的核医学治疗。
Int J Mol Sci. 2024 Jan 11;25(2):933. doi: 10.3390/ijms25020933.
2
A Systematic Review on Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA PET) Evaluating Localized Low- to Intermediate-Risk Prostate Cancer: A Tool to Improve Risk Stratification for Active Surveillance?一项关于前列腺特异性膜抗原正电子发射断层扫描（PSMA PET）评估局限性低至中危前列腺癌的系统评价：一种改善主动监测风险分层的工具？
Life (Basel). 2024 Jan 2;14(1):76. doi: 10.3390/life14010076.
3
Comparison of F-based PSMA radiotracers with [Ga]Ga-PSMA-11 in PET/CT imaging of prostate cancer-a systematic review and meta-analysis.
前列腺特异性膜抗原（PSMA）正电子发射断层扫描/计算机断层扫描（PET/CT）引导下的放疗对根治性前列腺切除术后生化复发患者的长期疗效：一项5年随访分析
Eur J Nucl Med Mol Imaging. 2025 Apr 5. doi: 10.1007/s00259-025-07255-6.
4
Size and SUV define the contribution of nodal metastases to PSA in oligorecurrent prostate cancer.大小和标准化摄取值定义了寡复发前列腺癌中淋巴结转移对前列腺特异性抗原的影响。
Prostate. 2025 Jan;85(1):105-111. doi: 10.1002/pros.24806. Epub 2024 Oct 9.
5
Theranostic digital twins: Concept, framework and roadmap towards personalized radiopharmaceutical therapies.治疗诊断学数字孪生：个性化放射性药物治疗的概念、框架和路线图。
Theranostics. 2024 May 27;14(9):3404-3422. doi: 10.7150/thno.93973. eCollection 2024.
6
Editorial: PET/CT and MRI in prostate cancer.社论：前列腺癌中的PET/CT与MRI
Front Oncol. 2024 May 24;14:1421542. doi: 10.3389/fonc.2024.1421542. eCollection 2024.
F 基 PSMA 放射性示踪剂与 [Ga]Ga-PSMA-11 在前列腺癌 PET/CT 成像中的比较：系统评价和荟萃分析。
Prostate Cancer Prostatic Dis. 2024 Dec;27(4):654-664. doi: 10.1038/s41391-023-00755-2. Epub 2023 Nov 28.
4
Administering [Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study.高危局限性前列腺癌男性患者在根治性前列腺切除术之前给予[镥]镥-PSMA-617（LuTectomy）：一项单中心、单臂、1/2期研究。
Eur Urol. 2024 Mar;85(3):217-226. doi: 10.1016/j.eururo.2023.08.026. Epub 2023 Oct 26.
5
PSMA Targeted Molecular Imaging and Radioligand Therapy for Prostate Cancer: Optimal Patient and Treatment Issues.PSMA 靶向分子成像与放射性配体治疗前列腺癌：最佳患者与治疗相关问题。
Curr Oncol. 2023 Aug 1;30(8):7286-7302. doi: 10.3390/curroncol30080529.
6
Presurgical Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial.术前 Ga-PSMA-11 正电子发射断层扫描用于生化复发风险评估：一项多中心前瞻性 3 期成像试验的随访分析。
Eur Urol. 2023 Dec;84(6):588-596. doi: 10.1016/j.eururo.2023.06.022. Epub 2023 Jul 21.
7
Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Active Surveillance for Prostate Cancer Trial (PASPoRT).镓-68 前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描在前列腺癌主动监测试验（PASPoRT）中的应用。
Eur Urol Oncol. 2024 Apr;7(2):204-210. doi: 10.1016/j.euo.2023.05.004. Epub 2023 Jun 7.
8
Joint EANM/SNMMI procedure guideline for the use of Lu-labeled PSMA-targeted radioligand-therapy (Lu-PSMA-RLT).EANM/SNMMI 联合实践指南：Lu 标记的 PSMA 靶向放射性配体治疗（Lu-PSMA-RLT）的应用。
Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2830-2845. doi: 10.1007/s00259-023-06255-8. Epub 2023 May 29.
9
Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis.前列腺特异性膜抗原正电子发射断层扫描与常规影像学方法在中高危前列腺癌初始分期中的诊断准确性的头对头比较：系统评价和荟萃分析。
Eur Urol. 2023 Jul;84(1):36-48. doi: 10.1016/j.eururo.2023.03.001. Epub 2023 Apr 7.
10
Histology and PSMA Expression on Immunohistochemistry in High-Risk Prostate Cancer Patients: Comparison with Ga-PSMA PET/CT Features in Primary Staging.高危前列腺癌患者的组织学及免疫组化中PSMA表达：与原发分期中Ga-PSMA PET/CT特征的比较
Cancers (Basel). 2023 Mar 10;15(6):1716. doi: 10.3390/cancers15061716.